NASDAQ:VLRX - Valeritas Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.59 +0.15 (+10.42 %)
(As of 05/20/2018 04:00 PM ET)
Previous Close$1.59
Today's Range$1.58 - $2.02
52-Week Range$1.19 - $7.20
Volume11.69 million shs
Average Volume1.26 million shs
Market Capitalization$35.60 million
P/E RatioN/A
Dividend YieldN/A
Beta4.45

About Valeritas (NASDAQ:VLRX)

Valeritas logoValeritas, Inc. is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company's portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin. Its development portfolio also includes the h-Patch technology, the Mini-Ject pre-filled needle-free delivery system and the Micro-Trans microneedle transdermal delivery patch. Its h-Patch is a controlled delivery technology platform designed to deliver drugs into subcutaneous tissue. The Mini-Ject represents needle-free injection system, combining a range of fully disposable pre-filled options. Micro-Trans microneedle array patch technology enables drug delivery into the dermis without limitations of drug size, structure, charge or the patient's skin characteristics.

Receive VLRX News and Ratings via Email

Sign-up to receive the latest news and ratings for VLRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VLRX
CUSIPN/A
Phone908-927-9920

Debt

Debt-to-Equity Ratio-2.57
Current Ratio2.56
Quick Ratio1.80

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$20.25 million
Price / Sales1.76
Cash FlowN/A
Price / CashN/A
Book Value($0.65) per share
Price / Book-2.45

Profitability

EPS (Most Recent Fiscal Year)($8.29)
Net Income$-49,300,000.00
Net Margins-225.97%
Return on Equity-1,768.69%
Return on Assets-90.30%

Miscellaneous

Employees103
Outstanding Shares22,390,000

Valeritas (NASDAQ:VLRX) Frequently Asked Questions

What is Valeritas' stock symbol?

Valeritas trades on the NASDAQ under the ticker symbol "VLRX."

How were Valeritas' earnings last quarter?

Valeritas Holdings (NASDAQ:VLRX) posted its earnings results on Wednesday, May, 9th. The company reported ($1.72) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($2.13) by $0.41. The company had revenue of $6.08 million for the quarter, compared to analysts' expectations of $6 million. Valeritas had a negative return on equity of 1,768.69% and a negative net margin of 225.97%. View Valeritas' Earnings History.

What price target have analysts set for VLRX?

2 Wall Street analysts have issued 12 month price targets for Valeritas' shares. Their predictions range from $12.00 to $12.00. On average, they anticipate Valeritas' stock price to reach $12.00 in the next year. View Analyst Ratings for Valeritas.

Who are some of Valeritas' key competitors?

When did Valeritas IPO?

(VLRX) raised $60 million in an IPO on Thursday, March 23rd 2017. The company issued 6,000,000 shares at $9.00-$11.00 per share. Cowen and Company and Wedbush PacGrow acted as the underwriters for the IPO and Roth Capital Partners and B. Riley & Co. were co-managers.

Has Valeritas been receiving favorable news coverage?

Press coverage about VLRX stock has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Valeritas earned a media sentiment score of 0.18 on Accern's scale. They also gave news coverage about the company an impact score of 44.79 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of Valeritas?

Shares of VLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Valeritas' stock price today?

One share of VLRX stock can currently be purchased for approximately $1.59.

How big of a company is Valeritas?

Valeritas has a market capitalization of $35.60 million and generates $20.25 million in revenue each year. The company earns $-49,300,000.00 in net income (profit) each year or ($8.29) on an earnings per share basis. Valeritas employs 103 workers across the globe.

How can I contact Valeritas?

Valeritas' mailing address is 750 ROUTE 202 SOUTH SUITE 600, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-927-9920 or via email at [email protected]


MarketBeat Community Rating for Valeritas (VLRX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  97 (Vote Outperform)
Underperform Votes:  62 (Vote Underperform)
Total Votes:  159
MarketBeat's community ratings are surveys of what our community members think about Valeritas and other stocks. Vote "Outperform" if you believe VLRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VLRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Valeritas (NASDAQ:VLRX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Valeritas in the last 12 months. Their average twelve-month price target is $12.00, suggesting that the stock has a possible upside of 654.72%. The high price target for VLRX is $12.00 and the low price target for VLRX is $12.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.673.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $12.00$11.00$11.00$11.00
Price Target Upside: 654.72% upside292.86% upside62.20% upside62.20% upside

Valeritas (NASDAQ:VLRX) Consensus Price Target History

Price Target History for Valeritas (NASDAQ:VLRX)

Valeritas (NASDAQ:VLRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/28/2018CowenDowngradeOutperform ➝ Market PerformHighView Rating Details
7/10/2017WedbushInitiated CoverageOutperform ➝ Outperform$12.00HighView Rating Details
5/17/2017B. RileyReiterated RatingBuy$10.00LowView Rating Details
(Data available from 5/20/2016 forward)

Earnings

Valeritas (NASDAQ:VLRX) Earnings History and Estimates Chart

Earnings by Quarter for Valeritas (NASDAQ:VLRX)

Valeritas (NASDAQ:VLRX) Earnings Estimates

2018 EPS Consensus Estimate: ($3.34)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.84)($0.84)($0.84)
Q2 20181($0.83)($0.83)($0.83)
Q3 20181($0.82)($0.82)($0.82)
Q4 20181($0.85)($0.85)($0.85)

Valeritas (NASDAQ VLRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018Q1 2018($2.13)($1.7220)$6.00 million$6.08 millionViewN/AView Earnings Details
2/26/2018Q4 2017($1.69)($2.57)$5.60 million$5.78 millionViewN/AView Earnings Details
11/8/2017Q3 2017($1.84)($1.62)$5.00 million$5.07 millionViewN/AView Earnings Details
8/11/2017Q2 2017($1.87)($1.83)$5.11 million$4.79 millionViewN/AView Earnings Details
5/12/2017Q1 2017($2.72)($6.92)$4.64 million$4.61 millionViewN/AView Earnings Details
2/21/2017Q4 2016($0.76)($0.77)$4.96 million$4.80 millionViewN/AView Earnings Details
11/10/2016Q3 2016($6.32)($5.60)$4.68 million$4.86 millionViewN/AView Earnings Details
8/10/2016Q2 2016($8.72)$4.89 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Valeritas (NASDAQ:VLRX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Valeritas (NASDAQ VLRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.20%
Institutional Ownership Percentage: 4.91%
Insider Trading History for Valeritas (NASDAQ:VLRX)

Valeritas (NASDAQ VLRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/10/2018Joseph M MandatoDirectorBuy20,000$1.63$32,600.00View SEC Filing  
5/8/2018Matt NguyenInsiderBuy5,000$1.62$8,100.00View SEC Filing  
4/25/2018John Edward TimberlakeInsiderBuy22,500$1.67$37,575.00View SEC Filing  
8/24/2017Joseph M MandatoDirectorBuy3,188$3.44$10,966.721,912View SEC Filing  
8/22/2017Joseph M MandatoDirectorBuy900$3.52$3,168.001,012View SEC Filing  
8/22/2017Matt NguygnInsiderBuy1,500$3.59$5,385.008,250View SEC Filing  
8/21/2017Joseph M MandatoDirectorBuy912$3.68$3,356.16112View SEC Filing  
8/18/2017John Edward TimberlakeInsiderBuy3,500$3.70$12,950.0031,037View SEC Filing  
5/31/2017John Edward TimberlakeInsiderBuy4,000$4.94$19,760.0027,037View SEC Filing  
5/22/2017Erick LuceraInsiderBuy1,500$4.95$7,425.004,000View SEC Filing  
5/18/2017Matt NguygnInsiderBuy1,000$4.73$4,730.006,000View SEC Filing  
5/17/2017John Edward TimberlakeInsiderBuy5,000$5.14$25,700.0023,037View SEC Filing  
3/28/2017Capital Royalty L.P.Major ShareholderBuy4,000,000$10.00$40,000,000.00View SEC Filing  
3/23/2017Brian K RobertsDirectorBuy800$10.00$8,000.00800View SEC Filing  
3/23/2017Erick LuceraCFOBuy3,000$10.00$30,000.003,000View SEC Filing  
3/23/2017Geoffrey JenkinsInsiderBuy600$10.00$6,000.006,850View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Valeritas (NASDAQ VLRX) News Headlines

Source:
DateHeadline
Critical Review: Valeritas (VLRX) & The CompetitionCritical Review: Valeritas (VLRX) & The Competition
www.americanbankingnews.com - May 20 at 5:16 PM
Valeritas (VLRX) & The Competition Financial ComparisonValeritas (VLRX) & The Competition Financial Comparison
www.americanbankingnews.com - May 20 at 3:09 AM
Two studies support value proposition of Valeritas V-Go Insulin Delivery device; shares up 21% premarketTwo studies support value proposition of Valeritas' V-Go Insulin Delivery device; shares up 21% premarket
seekingalpha.com - May 18 at 11:37 AM
Edited Transcript of VLRX earnings conference call or presentation 9-May-18 8:30pm GMTEdited Transcript of VLRX earnings conference call or presentation 9-May-18 8:30pm GMT
finance.yahoo.com - May 18 at 11:37 AM
Valeritas Announces Positive Clinical Results Across Two New Studies Evaluating V-Go® Wearable Insulin Delivery Device in Patients with Type 2 Diabetes Valeritas Announces Positive Clinical Results Across Two New Studies Evaluating V-Go® Wearable Insulin Delivery Device in Patients with Type 2 Diabetes 
finance.yahoo.com - May 18 at 11:37 AM
Financial Contrast: Valeritas (VLRX) and Its PeersFinancial Contrast: Valeritas (VLRX) and Its Peers
www.americanbankingnews.com - May 15 at 12:29 PM
Valeritas Holdings (VLRX) Director Purchases $32,600.00 in StockValeritas Holdings (VLRX) Director Purchases $32,600.00 in Stock
www.americanbankingnews.com - May 14 at 8:19 PM
Valeritas’ V-Go® Wearable Insulin Delivery Device Results in Clinical Benefits Sustained Over Time in Patients with DiabetesValeritas’ V-Go® Wearable Insulin Delivery Device Results in Clinical Benefits Sustained Over Time in Patients with Diabetes
finance.yahoo.com - May 14 at 11:27 AM
Zacks: Brokerages Set $15.00 Target Price for Valeritas Holdings (VLRX)Zacks: Brokerages Set $15.00 Target Price for Valeritas Holdings (VLRX)
www.americanbankingnews.com - May 12 at 11:13 PM
Critical Comparison: Valeritas (VLRX) & Its RivalsCritical Comparison: Valeritas (VLRX) & Its Rivals
www.americanbankingnews.com - May 12 at 7:19 PM
Valeritas (VLRX) Announces  Earnings Results, Beats Estimates By $0.41 EPSValeritas (VLRX) Announces Earnings Results, Beats Estimates By $0.41 EPS
www.americanbankingnews.com - May 10 at 6:33 PM
Valeritas (VLRX) CEO John Timberlake on Q1 2018 Results - Earnings Call TranscriptValeritas' (VLRX) CEO John Timberlake on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 10:43 AM
Valeritas Reports Record First Quarter Revenue with 32% Year-over-Year Growth and Gross Margins Expand to Record 47.6%Valeritas Reports Record First Quarter Revenue with 32% Year-over-Year Growth and Gross Margins Expand to Record 47.6%
finance.yahoo.com - May 10 at 10:43 AM
Analyzing K2M Group (KTWO) and Valeritas (VLRX)Analyzing K2M Group (KTWO) and Valeritas (VLRX)
www.americanbankingnews.com - May 9 at 12:50 PM
Valeritas (VLRX) vs. Its Competitors Head to Head SurveyValeritas (VLRX) vs. Its Competitors Head to Head Survey
www.americanbankingnews.com - May 7 at 10:18 AM
Financial Survey: Valeritas (VLRX) and Its RivalsFinancial Survey: Valeritas (VLRX) and Its Rivals
www.americanbankingnews.com - May 2 at 11:19 PM
Valeritas (VLRX) Stock Rating Upgraded by ValuEngineValeritas (VLRX) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 2 at 2:02 PM
Valeritas to Report First Quarter 2018 Results on May 9, 2018Valeritas to Report First Quarter 2018 Results on May 9, 2018
finance.yahoo.com - May 1 at 10:20 AM
Critical Review: Valeritas (VLRX) and Its RivalsCritical Review: Valeritas (VLRX) and Its Rivals
www.americanbankingnews.com - April 30 at 9:17 PM
Valeritas Presented New Data Demonstrating use of V-Go® Wearable Insulin Delivery Device Results in More Patients with Type 2 Diabetes Achieving Blood Glucose TargetsValeritas Presented New Data Demonstrating use of V-Go® Wearable Insulin Delivery Device Results in More Patients with Type 2 Diabetes Achieving Blood Glucose Targets
finance.yahoo.com - April 30 at 10:39 AM
Valeritas (VLRX) Announces V-Go Distribution Agreement in Australia and New Zealand (Earlier)Valeritas (VLRX) Announces V-Go Distribution Agreement in Australia and New Zealand (Earlier)
www.streetinsider.com - April 29 at 10:34 AM
Valeritas Holdings (VLRX) Insider Purchases $37,575.00 in StockValeritas Holdings (VLRX) Insider Purchases $37,575.00 in Stock
www.americanbankingnews.com - April 27 at 10:10 PM
 Valeritas Holdings (VLRX) Given Average Rating of "Buy" by Analysts Valeritas Holdings (VLRX) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 27 at 5:18 AM
Valeritas (VLRX) Prices 13.7M Common Stock Offering at $1.75/ShareValeritas (VLRX) Prices 13.7M Common Stock Offering at $1.75/Share
www.streetinsider.com - April 25 at 10:42 AM
Valeritas prices stock offering at $1.75; shares down 24% premarketValeritas prices stock offering at $1.75; shares down 24% premarket
seekingalpha.com - April 24 at 10:15 AM
Valeritas Announces Pricing of $24 Million Public Offering of Common StockValeritas Announces Pricing of $24 Million Public Offering of Common Stock
finance.yahoo.com - April 24 at 10:15 AM
Valeritas teams up with Glooko for more complete diabetes management solution; shares up 54%Valeritas teams up with Glooko for more complete diabetes management solution; shares up 54%
seekingalpha.com - April 20 at 3:46 PM
Valeritas Shares Surge on Australasia Distribution DealValeritas Shares Surge on Australasia Distribution Deal
www.baystreet.ca - April 17 at 3:51 PM
Varleritas establishes V-Go distribution in Australia/NZVarleritas establishes V-Go distribution in Australia/NZ
seekingalpha.com - April 17 at 10:45 AM
 Valeritas Holdings, Inc. (VLRX) Receives Average Recommendation of "Buy" from Brokerages Valeritas Holdings, Inc. (VLRX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 12 at 7:25 PM
Arch Therapeutics (ARTH) & Valeritas (VLRX) Head to Head SurveyArch Therapeutics (ARTH) & Valeritas (VLRX) Head to Head Survey
www.americanbankingnews.com - April 8 at 9:19 PM
Valeritas (VLRX) Downgraded by Cowen to Market PerformValeritas (VLRX) Downgraded by Cowen to Market Perform
www.americanbankingnews.com - March 28 at 8:06 AM
Zacks: Valeritas Holdings, Inc. (VLRX) Given $13.50 Consensus Price Target by AnalystsZacks: Valeritas Holdings, Inc. (VLRX) Given $13.50 Consensus Price Target by Analysts
www.americanbankingnews.com - March 26 at 11:10 PM
 Valeritas Holdings, Inc. (VLRX) Receives Consensus Recommendation of "Strong Buy" from Analysts Valeritas Holdings, Inc. (VLRX) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - March 21 at 10:36 AM
 Brokerages Set $13.50 Target Price for Valeritas Holdings, Inc. (VLRX) Brokerages Set $13.50 Target Price for Valeritas Holdings, Inc. (VLRX)
www.americanbankingnews.com - March 14 at 7:21 PM
Valeritas to Present at Upcoming Investor ConferencesValeritas to Present at Upcoming Investor Conferences
finance.yahoo.com - March 2 at 10:22 AM
Valeritas Holdings Inc (VLRX) Files 10-K for the Fiscal Year Ended on December 31, 2017Valeritas Holdings Inc (VLRX) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - March 1 at 10:11 AM
Valeritas Reports Fourth Quarter and Full Year 2017 Financial ResultsValeritas Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - February 26 at 4:07 PM
Valeritas Holdings, Inc. to Host Earnings CallValeritas Holdings, Inc. to Host Earnings Call
finance.yahoo.com - February 26 at 4:07 PM
Brokerages Expect Valeritas Holdings, Inc. (VLRX) to Post ($1.69) Earnings Per ShareBrokerages Expect Valeritas Holdings, Inc. (VLRX) to Post ($1.69) Earnings Per Share
www.americanbankingnews.com - February 24 at 3:38 PM
Valeritas Announces V-Go® Distribution Agreement in Italy with Movi SpAValeritas Announces V-Go® Distribution Agreement in Italy with Movi SpA
finance.yahoo.com - February 22 at 10:13 AM
Valeritas Holdings, Inc. (VLRX) Expected to Announce Quarterly Sales of $5.60 MillionValeritas Holdings, Inc. (VLRX) Expected to Announce Quarterly Sales of $5.60 Million
www.americanbankingnews.com - February 17 at 1:50 AM
 Valeritas Holdings, Inc. (VLRX) Given $13.50 Average Target Price by Brokerages Valeritas Holdings, Inc. (VLRX) Given $13.50 Average Target Price by Brokerages
www.americanbankingnews.com - February 16 at 9:14 PM
Valeritas Presents Data Demonstrating V-Go® Wearable Insulin Delivery Device Significantly Reduces A1C and Insulin Requirements in Patients with Type 2 Diabetes, When Combined with a Simplified Insulin Titration AlgorithmValeritas Presents Data Demonstrating V-Go® Wearable Insulin Delivery Device Significantly Reduces A1C and Insulin Requirements in Patients with Type 2 Diabetes, When Combined with a Simplified Insulin Titration Algorithm
finance.yahoo.com - February 15 at 9:25 AM
Valeritas Presents Data Demonstrating V-Go® Wearable Insulin Delivery Device Significantly Reduces A1C and Insulin Requirements in Patients with Type 2 Diabetes, When Combined with a Simplified Ins...Valeritas Presents Data Demonstrating V-Go® Wearable Insulin Delivery Device Significantly Reduces A1C and Insulin Requirements in Patients with Type 2 Diabetes, When Combined with a Simplified Ins...
finance.yahoo.com - February 15 at 9:25 AM
Valeritas to Host Investor Meetings at the 2018 BTIG Medical Technology, Life Science, and Diagnostic Tools ConferenceValeritas to Host Investor Meetings at the 2018 BTIG Medical Technology, Life Science, and Diagnostic Tools Conference
finance.yahoo.com - February 9 at 8:31 AM
Valeritas (VLRX) Upgraded to "Sell" by ValuEngineValeritas (VLRX) Upgraded to "Sell" by ValuEngine
www.americanbankingnews.com - February 4 at 12:44 PM
 Analysts Anticipate Valeritas Holdings, Inc. (VLRX) Will Post Quarterly Sales of $5.60 Million Analysts Anticipate Valeritas Holdings, Inc. (VLRX) Will Post Quarterly Sales of $5.60 Million
www.americanbankingnews.com - February 1 at 8:04 AM
 Valeritas Holdings, Inc. (VLRX) Given $13.50 Average Price Target by Brokerages Valeritas Holdings, Inc. (VLRX) Given $13.50 Average Price Target by Brokerages
www.americanbankingnews.com - January 30 at 7:32 AM
Valeritas Announces its V-Go® Wearable Insulin Delivery Device is now available in Puerto RicoValeritas Announces its V-Go® Wearable Insulin Delivery Device is now available in Puerto Rico
finance.yahoo.com - January 17 at 10:19 AM

SEC Filings

Valeritas (NASDAQ:VLRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Valeritas (NASDAQ:VLRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Valeritas (NASDAQ VLRX) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.